Prescription drug costs account for an increasingly large fraction of overall health care costs in the developed world. Given this and the increased scrutiny paid to the large profits reported by the pharmaceutical industry, it is not surprising that reducing drug costs, while simultaneously maintaining health care quality, is an important goal. Promotion of generic drug use is a key strategy in this effort.
Despite the individual and societal benefits associated with lowering drug costs, generic drugs are underused. This is occurring even in the face of compelling evidence from bioequivalence and randomized controlled trials supporting the equivalence of generic drug products1 and efforts from payers to move patients and prescribers toward generics (eg, tiered pharmacy benefits and prior authorization for less cost-effective agents). As Green et al2 point out, the adoption of generic statins to decrease coronary heart disease risk has been slow and disappointingly incomplete, given the equivalence (in terms of clinical efficacy and safety) of generic-available and brand-only statins.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
In their commentary on generic drug use (1), Alldredge and Kayser state that, “In 2011, fewer prescriptions for generic simvastatin were written than for [branded] Lipitor despite a significant cost differential and no apparent clinical differences in efficacy and safety”. That statement seems to be in conflict with the views of the FDA. On June 8, 2011, the FDA issued a safety warning concerning simvastatin (2), in which physicians were advised to discontinue the use of simvastatin 80 mg (except in patients who had already been taking it safely for over one year). In addition, FDA advised that the dose of simvastatin should not exceed 10 mg for patients taking diltiazem or verapamil, and that, when prescribed to patients taking amlodipine, the maximum dose of simvastatin should be 20 mg. These safety warnings were based on reports of serious myopathy-related adverse events caused by simvastatin 80 mg, or by lower doses of simvastatin when combined with widely-prescribed calcium-channel blockers. Clinicians now have a maximum safe simvastatin dose of 40 mg, which lowers LDL cholesterol levels by about 40%, while atorvastatin 80 mg reduces LDL by about 55% (3). To date, the FDA has not deemed it necessary to issue such stringent safety restrictions on the use of atorvastatin.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
Statin Dosing and LDL Levels
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.